DSC
UTHR icon

Duncker Streett & Co’s United Therapeutics UTHR Stock Holding History

Duncker Streett & Co’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-3,025
Closed -$268K – 639
2014
Q2 		$268K Sell
3,025
-200
-6% -$19.2K 0.09% 228
2014
Q1 		$303K Buy
+3,225
New +$330K 0.11% 204

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Duncker Streett & Co's UTHR Position: Q3 2014 in Review

Duncker Streett & Co sold out of United Therapeutics (UTHR) in Q3 2014, closing a stake of 3,025 shares — an estimated $268K sold.

Duncker Streett & Co first reported a position in UTHR in Q1 2014 and held it in 2 quarters. The position peaked at $303K in Q1 2014. 319 funds tracked by Wall St. Rank hold UTHR as of Q3 2014.

  • Duncker Streett & Co reported no remaining United Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Duncker Streett & Co sold 3,025 United Therapeutics shares in Q3 2014, an estimated $268K.
  • Duncker Streett & Co first reported a position in United Therapeutics in Q1 2014 and held it in 2 quarters.
  • Duncker Streett & Co's United Therapeutics position peaked at $303K in Q1 2014.
  • 319 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2014.

Based on Duncker Streett & Co's 13F filing for Q3 2014, filed 23 Oct 2014.